Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

   Active, not recruiting · Phase 3 · Hidradenitis Suppurativa

   NCT06468228 · AbbVie Inc. · 66 U.S. investigators

   $7.8Mresearch payments

2. Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma

   Completed · Phase 2 · Asthma

   NCT06102005 · Sanofi US Services Inc. · 48 U.S. investigators

   $7.7Mresearch payments

3. A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

   Active, not recruiting · Phase 3 · Relapsed/Refractory Follicular Lymphoma

   NCT05100862 · Beigene, Ltd. · 48 U.S. investigators

   $7.7Mresearch payments

4. Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older

   Active, not recruiting · Phase 1, Phase 2 · Pandemic Influenza Immunization

   NCT06907511 · Sanofi Pasteur Inc. · 13 U.S. investigators

   $7.7Mresearch payments

5. A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

   Active, not recruiting · Phase 3 · Obesity

   NCT05869903 · Eli Lilly and Company · 61 U.S. investigators

   $7.6Mresearch payments

6. A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants

   Completed · Phase 1 · Healthy

   NCT06475729 · Eli Lilly and Company · 6 U.S. investigators

   $7.6Mresearch payments

7. Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

   Active, not recruiting · Phase 3 · Stage I Chronic Lymphocytic Leukemia

   NCT01886872 · AbbVie Inc. · 1 U.S. investigator

   $7.6Mresearch payments

8. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

   Recruiting · Phase 3 · Carcinoma, Non-Small-Cell Lung

   NCT06119581 · Eli Lilly and Company · 82 U.S. investigators

   $7.4Mresearch payments

9. A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

   Active, not recruiting · Phase 3 · Melanoma

   NCT05608291 · Regeneron Pharmaceuticals, Inc. · 26 U.S. investigators

   $7.4Mresearch payments

10. Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

    Completed · Phase 3 · Psoriasis

    NCT06588283 · Eli Lilly and Company · 75 U.S. investigators

    $7.3Mresearch payments

11. Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

    Completed · Phase 3 · Psoriatic Arthritis

    NCT06588296 · Eli Lilly and Company · 88 U.S. investigators

    $7.2Mresearch payments

12. A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

    Completed · Phase 2 · Influenza

    NCT06864143 · ModernaTX, Inc. · 17 U.S. investigators

    $7.2Mresearch payments

13. A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

    Completed · Phase 2 · Hidradenitis Suppurativa

    NCT06046729 · Eli Lilly and Company · 39 U.S. investigators

    $7.1Mresearch payments

14. Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

    Active, not recruiting · Phase 3 · GEP-NET

    NCT05477576 · E.r. Squibb & Sons, L.l.c. · 45 U.S. investigators

    $7.0Mresearch payments

15. Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

    Active, not recruiting · Phase 3 · Diabetes Mellitus, Type 2

    NCT06260722 · Eli Lilly and Company · 49 U.S. investigators

    $7.0Mresearch payments

16. SIMPLAAFY Clinical Trial

    Active, not recruiting · Not applicable · Atrial Fibrillation

    NCT06521463 · Boston Scientific Corporation · 86 U.S. investigators

    $6.8Mresearch payments

17. Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

    Active, not recruiting · Phase 3 · Multiple Sclerosis

    NCT06141473 · Genzyme Corporation · 87 U.S. investigators

    $6.7Mresearch payments

18. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

    Recruiting · Phase 3 · Melanoma

    NCT06246916 · Regeneron Pharmaceuticals, Inc. · 80 U.S. investigators

    $6.7Mresearch payments

19. A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

    Recruiting · Phase 3 · Psychosis Associated With Alzheimer's Disease

    NCT05511363 · E.r. Squibb & Sons, L.l.c. · 38 U.S. investigators

    $6.6Mresearch payments

20. A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

    Completed · Phase 1, Phase 2 · Cytomegalovirus

    NCT05575492 · ModernaTX, Inc. · 47 U.S. investigators

    $6.5Mresearch payments

21. Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)

    Terminated · Phase 3 · Angelman Syndrome

    NCT06617429 · Ultragenyx Pharmaceutical Inc. · 16 U.S. investigators

    $6.4Mresearch payments

22. HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

    Active, not recruiting · Phase 1 · Non-Small Cell Lung Cancer (NSCLC)

    NCT04676477 · Daiichi Sankyo Inc. · 15 U.S. investigators

    $6.3Mresearch payments

23. A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

    Active, not recruiting · Phase 3 · GIST

    NCT05734105 · Deciphera Pharmaceuticals Inc. · 20 U.S. investigators

    $6.2Mresearch payments

24. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

    Recruiting · Phase 1 · Mesothelioma

    NCT05245500 · E.r. Squibb & Sons, L.l.c. · 22 U.S. investigators

    $6.1Mresearch payments

25. A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

    Active, not recruiting · Phase 3 · Chronic Lymphocytic Leukemia

    NCT04965493 · Eli Lilly and Company · 57 U.S. investigators

    $6.1Mresearch payments

26. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    Recruiting · Phase 3 · Alzheimer Disease

    NCT06585787 · E.r. Squibb & Sons, L.l.c. · 79 U.S. investigators

    $6.0Mresearch payments

27. A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

    Completed · Phase 3 · OSA

    NCT06649045 · Eli Lilly and Company · 20 U.S. investigators

    $6.0Mresearch payments

28. A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943

    Completed · Phase 1 · Obesity

    NCT06313528 · Eli Lilly and Company · 2 U.S. investigators

    $5.9Mresearch payments

29. Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

    Active, not recruiting · Phase 3 · Migraine

    NCT06417775 · AbbVie Inc. · 108 U.S. investigators

    $5.9Mresearch payments

30. A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

    Completed · Phase 3 · Overweight

    NCT06047548 · Eli Lilly and Company · 24 U.S. investigators

    $5.9Mresearch payments

31. Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

    Active, not recruiting · Phase 1, Phase 2 · Advanced Cancer

    NCT03785249 · Mirati Therapeutics, Inc. · 77 U.S. investigators

    $5.9Mresearch payments

32. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

    Active, not recruiting · Phase 3 · Obesity

    NCT07035093 · Eli Lilly and Company · 18 U.S. investigators

    $5.7Mresearch payments

33. First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

    Recruiting · Phase 1, Phase 2 · Advanced Solid Tumor

    NCT05875168 · Daiichi Sankyo Inc. · 7 U.S. investigators

    $5.7Mresearch payments

34. Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older

    Completed · Phase 1, Phase 2 · Influenza Immunization

    NCT06727058 · Sanofi Pasteur Inc. · 14 U.S. investigators

    $5.7Mresearch payments

35. A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

    Completed · Phase 3 · Type 2 Diabetes Mellitus

    NCT04255433 · Eli Lilly and Company · 130 U.S. investigators

    $5.6Mresearch payments

36. Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

    Active, not recruiting · Phase 1, Phase 2 · Carcinoma, Non-Small-Cell Lung

    NCT04956640 · Eli Lilly and Company · 24 U.S. investigators

    $5.6Mresearch payments

37. A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

    Recruiting · Phase 1 · Ovarian Neoplasms

    NCT06400472 · Eli Lilly and Company · 9 U.S. investigators

    $5.6Mresearch payments

38. Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

    Completed · Phase 2 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    NCT04116437 · Beone Medicines Ltd. · 25 U.S. investigators

    $5.5Mresearch payments

39. First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

    Active, not recruiting · Phase 1 · Hormone Receptor Positive Breast Cancer

    NCT03401385 · Daiichi Sankyo Inc. · 12 U.S. investigators

    $5.5Mresearch payments

40. A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

    Completed · Phase 3 · Type 2 Diabetes

    NCT05929079 · Eli Lilly and Company · 50 U.S. investigators

    $5.5Mresearch payments

41. Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

    Completed · Phase 1, Phase 2 · COVID-19 Immunization

    NCT06695130 · Sanofi Pasteur Inc. · 12 U.S. investigators

    $5.3Mresearch payments

42. A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

    Active, not recruiting · Phase 1, Phase 2 · Advanced Solid Tumors

    NCT04626635 · Regeneron Pharmaceuticals, Inc. · 19 U.S. investigators

    $5.3Mresearch payments

43. INDV-6001 Multiple-Dose Pharmacokinetic Study

    Completed · Phase 2 · Moderate to Severe Opioid Use Disorder

    NCT06576843 · Indivior Inc. · 10 U.S. investigators

    $5.2Mresearch payments

44. Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

    Completed · Phase 1, Phase 2 · COVID-19 Immunization

    NCT06695117 · Sanofi Pasteur Inc. · 12 U.S. investigators

    $5.2Mresearch payments

45. A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD

    Completed · Phase 3 · Chronic Obstructive Pulmonary Disease

    NCT06208306 · Sanofi US Services Inc. · 69 U.S. investigators

    $5.1Mresearch payments

46. A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

    Recruiting · Phase 3 · Uterine Fibroids

    NCT05862272 · Sumitomo Pharma America, Inc. · 125 U.S. investigators

    $4.9Mresearch payments

47. Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

    Active, not recruiting · Phase 3 · Multiple Sclerosis

    NCT06141486 · Genzyme Corporation · 92 U.S. investigators

    $4.9Mresearch payments

48. A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

    Completed · Phase 3 · Obesity

    NCT05872620 · Eli Lilly and Company · 47 U.S. investigators

    $4.8Mresearch payments

49. Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

    Enrolling by invitation · Phase 3 · Idiopathic Pulmonary Fibrosis

    NCT04905693 · United Therapeutics Corporation · 87 U.S. investigators

    $4.8Mresearch payments

50. Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

    Active, not recruiting · Phase 1 · Advanced Solid Tumors

    NCT05599984 · AbbVie Inc. · 27 U.S. investigators

    $4.7Mresearch payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.